Whiteman, Kathleen R.,O'Leary, James J.,Lutz, Robert John,OLeary, James J.
申请号：
AU2012240448
公开号：
AU2012240448A1
申请日:
2012.03.29
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
The disclosure relates to anti-cancer drug combinations, pharmaceutical compositions for treating ovarian, peritoneal, or fallopian tube cancer. Specifically, the disclosure is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound (e.g." an immunoconjugate) in combination with a chemotherapeutic agent (in particular a gemcitabine compound, a topotecan compound, and a doxorubicin compound), improves the therapeutic index in the treatment of ovarian, peritoneal, or fallopian tube cancer over and above the additive effects of the anticancer agents used alone. Combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus an additional chemotherapeutic agent have a synergistic effect in the ovarian cancer therapeutic index. Further disclosed are methods of modulating the growth of selected cell populations, such as ovarian, peritoneal, or fallopian tube cancer cells, by administering a therapeutically effective amount of such combinations.
